CK18+ DTCs were detected in 38.9% of esophageal cancer patients, but co-expression of EpCAM was seen in only 37.1% of DTC-positive cases, whereas 62.9% of patients showed CK18+/EpCAM low/negative DTCs. Here, EPCAM is linked to esophageal cancer.